Argentina Medical Device Registration: 27 ANMAT FAQs on GMP and Imports (2026)

These 27 questions cover Argentina’s regulatory framework, classification rules, registration pathways, submission documents, timelines and fees, import clearance, post-market vigilance and registration holding strategies. The answers have been checked against official Argentine sources: the ANMAT website, the Boletin Oficial (Argentine Official Gazette) and the original MERCOSUR regulation GMC 25/21. Regulatory information is current through October 2026.

Two features of the market deserve attention.

First, Argentina is Latin America’s third-largest medical device market, with a population of more than 46 million. Its public health system covers approximately half the population, its private healthcare network is well developed, domestic production of high-end devices is limited, and reliance on imports has long remained high. For Chinese manufacturers, it is one of the most significant entry points in the Southern Cone.

Second, Argentina has undergone its most significant regulatory shift in nearly two decades since 2025. Disposicion ANMAT 64/2025 incorporated MERCOSUR’s new Technical Regulation on Medical Device Registration (GMC 25/21) into domestic law and formally repealed Disposicion 2318/02, which had been in use for 23 years. ANMAT also introduced Disposiciones 8799/2025 on simplified company authorisation for low-risk products, 4446/2025 on import facilitation for low-risk products, and 224/2026 on imports of used and refurbished equipment. Applying outdated experience to the new rules is now a common source of compliance errors.

The following 27 questions explain the current framework.

1. Regulatory framework (Q1-Q5)

The first issue is who regulates medical devices and on what legal basis. Argentina regulates the entire medical device lifecycle. Company authorisation and product registration are two independent market access requirements, and a product cannot be sold legally if either is missing.

Q1. Which authority regulates medical devices in Argentina?

ANMAT, the Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica (National Administration of Drugs, Food and Medical Technology), regulates medical devices under Argentina’s Ministry of Health. It was established and operates under Ley 16.463, the 1966 law on health products, and Decreto 1490/92. ANMAT is also an observer of the International Medical Device Regulators Forum (IMDRF).

Its internal responsibilities are divided among specialised units. The National Institute of Medical Products (INPM) conducts technical reviews and registrations, and approved products are entered in the Register of Medical and Technology Products (RPPTMI). The Directorate of Post-Market Vigilance and Regulatory Actions (DVPCyAR) handles post-market oversight. ANMAT’s full-lifecycle controls comprise company authorisation (habilitacion), product registration (registro), GMP and post-market vigilance. These are independent requirements, and all four must be satisfied.

Q2. What are the core regulations?

Ley 16.463 is the overarching law. The principal implementing regulations are:

Administrative penalties and criminal liability are based principally on Ley 16.463 and Decreto 341/92.

Q3. Which regulation governs registration, and has 2318/02 been repealed?

Yes, it has been repealed. The current principal regulation is Disposicion ANMAT 64/2025, signed on 4 January 2025 and published in the Official Gazette on 13 January 2025. Its two principal effects are:

1. It incorporates MERCOSUR/GMC/RES Resolution No. 25/21, the MERCOSUR Technical Regulation on Medical Device Registration, adopted in Montevideo on 13 October 2021, into Argentine domestic law in full. That resolution had itself repealed the earlier GMC 40/00.

2. It expressly repeals Disposiciones ANMAT 2318/02 and 1285/04.

Under MERCOSUR’s Ouro Preto mechanism for simultaneous entry into force, GMC 25/21 takes effect uniformly after all States Parties have incorporated it into domestic law. Argentina has completed that incorporation, and ANMAT’s current published procedures apply Disposicion 64/25. For manufacturers, the immediate consequence is that GMC 25/21 and its Annexes I-V are now the current master texts for classification rules, registration procedures, document lists and labelling requirements.

Q4. How does Argentina define a medical device?

Disposicion 64/25 defines a medical device as any instrument, apparatus, equipment, implant, in vitro diagnostic product, computer program (software), material or other article intended by the manufacturer to be used, alone or in combination, on human beings for a specific medical purpose, whose principal intended action is not achieved by pharmacological, immunological or metabolic means, although such means may assist its function.

The specified purposes include diagnosis, prevention, monitoring, treatment or alleviation of disease; diagnosis, monitoring, treatment or repair of injury or disability; investigation, replacement or modification of anatomy or of a physiological or pathological process; supporting or sustaining life; control of or assistance with conception; and obtaining information through in vitro examination of specimens derived from the human body, including for organ and tissue donation.

Two points merit attention. Software is expressly included in the definition, and the definition closely aligns with the EU MDR. Manufacturers that already maintain CE or FDA technical documentation therefore face relatively lower adaptation costs.

Q5. Which regulations apply to IVDs and used equipment?

Two separate cases apply:

– IVDs: these products fall outside the scope of GMC 25/21 and are regulated separately under Disposicion 2198/2022. They are divided by risk into Groups A, B, C and D. Group A includes products such as buffers, diluents, culture media and specimen preparation instruments; Group B includes instruments providing quantitative analytical results, except for self-testing; Group C includes blood grouping and tissue typing; and Group D includes tests for blood-borne pathogens and pathogens associated with a high risk of fatality. Labels must also comply with Disposicion 2674/99.

– Used and refurbished equipment: these products also fall outside GMC 25/21. Disposicion 224/2026, published on 2 February 2026, establishes an import framework covering three scenarios: refurbishment abroad followed by import, used equipment that does not require mandatory refurbishment, and import for refurbishment within Argentina. Single-use devices may not be imported under this framework. Required evidence includes the original manufacturer’s refurbishment certificate, an assessment of remaining service life, evidence of compliance with current safety and performance standards, and specific labelling identifying the product as refurbished. Class I/II products are subject to notification within 48 hours after customs clearance, while Class III/IV products require prior ANMAT authorisation.

2. Risk classification (Q6-Q9)

Classification determines the registration pathway, documentation and timeline. Argentina applies MERCOSUR’s harmonised four-level risk classification. Each product must be assessed against the 22 rules individually; classification cannot be established through analogy or direct conversion from another jurisdiction.

Q6. How does the classification system work?

Products are assigned to Classes I-IV according to their inherent risk to users, patients, operators or third parties, using the 22 classification rules in Annex II of GMC 25/21. The rules fall into four groups:

1. Non-invasive rules (Rules 1-4), covering products such as those that contact injured skin or mucous membranes or store or channel blood, other body liquids or gases.

2. Invasive rules (Rules 5-8), which distinguish between entry through a body orifice and surgical invasion and between transient, short-term and long-term use.

3. Active device rules (Rules 9-13), covering treatment, diagnosis and monitoring, software under Rule 11, and administration of medicinal products.

4. Special rules (Rules 14-22), covering devices incorporating medicinal components, contraception, disinfection and sterilisation, X-ray imaging, cells and tissues, nanomaterials, and administration by inhalation, among others.

Three time thresholds are important: short-term use means continuous use from 60 minutes to 30 days, long-term use means more than 30 days, and transient use means less than 60 minutes. If classification remains uncertain, the competent health authority decides under Article 2 of Part II of GMC 25/21. A company may submit an unclassified product enquiry through the TAD system and wait for ANMAT’s opinion before filing.

Q7. How do China’s Classes I, II and III correspond to Argentine classes?

There is no direct conversion. Each product must be assessed independently against all 22 rules. A common mistake is to equate sterile supply or a measuring function automatically with high risk. Argentine rules also consider sterility, but give it a different weight from the NMPA framework. A Chinese Class II sterile surgical instrument may therefore fall into Class I in Argentina. Where a product is non-sterile, has no measuring function, is not active and appears on the relevant list, the most streamlined sworn declaration pathway may apply.

Differences are more significant for products containing software, assessed separately under Rule 11; implants under Rule 8; devices incorporating medicinal components under Rule 14; and nanomaterials under Rule 19. A rule-by-rule review should address five dimensions: intended purpose, invasiveness, duration of use, contact with the heart, central nervous system or circulatory system, and whether the device is active. An official classification enquiry should be considered when necessary.

Q8. How are implantable products classified?

Rule 8 is the central provision. Implantable devices and surgically invasive devices for long-term use, meaning more than 30 days, are Class III, subject to three exceptions:

Devices placed in the teeth -> Class II; devices in direct contact with the heart, circulatory system or central nervous system -> Class IV; and devices that produce a biological effect or are wholly or mostly absorbed by the body -> Class IV.

The legal definition of implantation must first be established. It covers products that are wholly introduced into the human body, replace an epithelial surface or the surface of the eye through medical intervention and remain after the procedure, and products partially introduced into the human body through medical intervention that remain for at least 30 days after the procedure. Coronary stents, cardiac pacemakers, artificial heart valves and implantable defibrillators are therefore Class IV, while orthopaedic implants, intraocular lenses and hernia repair meshes are generally Class III.

Q9. How is software as a medical device (SaMD) classified?

Rule 11 specifically governs software, using the following logic:

Software that provides information used to make treatment or diagnostic decisions -> Class II. If an erroneous decision could lead to death or an irreversible deterioration in health -> Class IV. If it could lead to a serious deterioration in health or require surgical intervention -> Class III.

Software that monitors physiological processes -> Class II. If it monitors vital parameters whose variations could pose an immediate danger to the patient, such as cardiac rhythm, respiration or central nervous system activity -> Class III.

All other software -> Class I.

Related points include the following: mobile apps that meet the definition are also SaMD, and software that is not part of another medical device is classified independently. On 10 September 2026, ANMAT further clarified that health apps in wearable devices such as smartwatches also fall within the regulatory boundary. For AI products, internal records should map each model version to the corresponding software version and registration number, with a defined process for determining which updates constitute reportable changes.

3. Registration pathways and submissions (Q10-Q17)

This section addresses who may apply, which documents are required and how long review takes.

Q10. What registration pathways are available?

There are three risk-based routes, reflecting the principal facilitation introduced by the 2025 reform:

1. Sworn declaration (Declaracion Jurada): available only to the narrowest low-risk category, namely Class I products that are non-sterile, have no measuring function, are not active and appear on the relevant list. The sworn declaration signed by INPM serves as evidence of RPPTMP registration.

2. Declaration of conformity (Declaracion de Conformidad): applies to all other Class I products and all Class II products. INPM reviews the sworn documents, and the signed declaration of conformity serves as evidence of registration without a full technical review.

3. Standard registration with full technical review: applies to Class III/IV products. The applicant submits a complete technical dossier, and ANMAT grants registration by administrative act after technical review and assigns a PM registration number.

GMC 25/21 expressly authorises Member States to use simplified procedures for Class I/II products, and Argentina has implemented the first two streamlined routes on that basis. The same principle applies to IVDs: Groups A/B use the declaration of conformity route, while Groups C/D undergo full review.

Q11. Can a foreign manufacturer apply directly to ANMAT?

No. Argentina does not accept direct applications from foreign manufacturers. A locally established Argentine company, acting as importer or legal representative, must submit the application as the applicant (solicitante) and hold the registration. The local entity therefore controls three core assets: the registration certificate, import rights and the official communication channel with ANMAT. Selecting the registration holder establishes the compliance structure for the Argentine market; see Q25.

Q12. What qualifications and responsibilities does the local registration holder have?

Qualification requirements are: a legally established Argentine legal entity; operating authorisation for manufacturing and/or import under Disposicion 2319/2002; a BPF compliance certificate issued by ANMAT under Disposicion 3266/2013; and a qualified Technical Director (Director Tecnico) registered with ANMAT, who must be a licensed professional with a university degree and appropriate technical competence. All registration documents must be signed jointly by the legal representative and the Technical Director.

As registration holder, the entity bears local legal responsibility for product quality, safety and performance; retains the technical dossier for inspection; handles all import matters as importer; fulfils post-market vigilance obligations; manages renewals and variations; and is responsible for the truthfulness of submitted information. A false sworn declaration may result in administrative or even criminal liability under Article 110 of Decreto 1759/72.

Q13. What are the core submission documents?

Article 6 of Part III of GMC 25/21 lists five categories of basic documents:

1. Proof of fee payment.

2. Identification information for the manufacturer, importer and product, using the formats in Annexes III, IV and V and signed by the legal representative and Technical Director.

3. Manufacturer’s letter of authorisation: valid for two years from issuance, expressly authorising the Argentine importer to represent and sell its products in Argentina, stating both parties’ legal names and full addresses, and legalised or apostilled with an accompanying translation.

4. Registration certificate or certificate of free sale from the country of origin or sale: if no expiry date is stated, valid for two years from issuance, with legalisation or an apostille and an accompanying translation.

5. Evidence of conformity with product-specific technical regulations.

In practice, the dossier also requires an ISO 13485 certificate, Spanish labels and IFU, a technical report in the Annex V format covering product description and operating principle, intended use, precautions, manufacturing process, and a description of safety and performance against the essential requirements of GMC 72/98, plus an ISO 14971 risk management report and test reports. Class III/IV applications normally require clinical evaluation information. If the technical report does not adequately demonstrate safety and performance, ANMAT will require a clinical investigation of the product.

Q14. What requirements apply to the certificate of free sale (CFS)?

The CFS is a mandatory document, and its authentication chain is a frequent source of deficiencies for Chinese manufacturers. The key points are:

– It must be issued by the competent authority of the country where the product is manufactured and/or sold.

– Reference jurisdictions recognised in industry practice include the United States, EU Member States, the United Kingdom, Japan, Australia, Canada, Israel and the EFTA countries (Switzerland, Norway, Iceland and Liechtenstein). Registration evidence from a recognised reference jurisdiction is preferable. If only a Chinese FSC is available, ANMAT is likely to require an Argentine quality system application and may require a factory inspection.

– A certificate without a stated expiry date is valid for two years from issuance.

– The document must carry an apostille or consular legalisation and be accompanied by a certified Spanish translation.

Chinese manufacturers generally obtain an apostille for the NMPA Certificate for Export Sale of Medical Device Products. Missing authentication, missing translations and expired documents are three frequent reasons for deficiency notices.

Q15. What GMP and quality system requirements apply?

Two levels of requirements apply, and both must be satisfied:

Foreign manufacturers: provide a current ISO 13485:2016 certificate issued by a certification body with appropriate accreditation and covering the products in the application, or other equivalent GMP evidence. ANMAT retains the right to conduct a GMP inspection at the manufacturing site, with a higher likelihood for Class III/IV products.

Local importers and registration holders: obtain a BPF compliance certificate (Certificado de Cumplimiento de BPF) issued by ANMAT under Disposicion 3266/2013. The certificate is valid for five years and is obtained through the procedures in Disposiciones 7425/13 and 2096/22; the standard procedure takes approximately 60 business days.

Disposicion 8799/2025, issued in November 2025, provides a simplified authorisation route for companies handling Class I/II devices and Group A/B IVDs, but it does not reduce GMP requirements. Companies must still comply with Disposicion 3266/13, retain supporting evidence and undergo periodic ANMAT inspections.

Q16. What are the language requirements?

All submission documents, labels and instructions for use (IFU) must be in Spanish. Documents in other languages must be accompanied by certified sworn or official translations. The quality of the Spanish technical documentation directly affects review efficiency, because terminology errors can trigger deficiency requests or questions. An Argentine regulatory translator should be used rather than relying on machine translation.

Q17. What are the official review timelines and practical total timelines?

The official administrative review windows are:

After acceptance, a formal review takes approximately 10 consecutive days. If the dossier is incomplete, the applicant receives a single deficiency notice and must submit the corrections within 30 business days. The review clock stops while corrections are pending.

The practical end-to-end timeline is approximately 3-6 months for Class I/II, including document preparation and the authentication chain. Class III/IV generally takes 12-15 months or longer. Deficiency rounds, GMP inspection scheduling and peso exchange rate fluctuations can extend the timeline. After approval, the product is entered in the HELENA public database, where its registration number can be verified publicly. This is the most direct way to identify a purported registration that is not genuine.

4. Labelling, fees and validity (Q18-Q20)

Fees and key dates after approval should be planned in advance.

Q18. What must labels and IFU contain?

Under Annex IV of GMC 25/21, which updates Annex III.B of the former Disposicion 2318/02, labels and IFU must be in Spanish. Labels must state at least:

– The legal names and full addresses of the manufacturer and importer (registration holder). If the manufacturer’s country differs from the country of the registration holder’s legal entity, the country of origin must be stated.

– The registration number, prefixed by the identifying abbreviation of the competent authority.

– The lot number, identified by the word lote, or the serial number.

– The manufacturing date and expiry or use-by date.

– The word esteril (sterile), where applicable.

– A single-use designation, where applicable.

– Storage and transport conditions, sterilisation method where applicable, and the Technical Director’s name.

Safe-use information must be presented clearly and legibly. A kit composed of registered products in their intact original packaging may be exempt from separate combined registration, but its label and IFU must still state the registration information for each component.

Q19. What are the official fees?

Fees are paid by product category under ANMAT’s fee schedule (arancel), whose legal basis is Disposicion 2319/02 and its amendments. Recent fee schedules provide the following reference amounts: approximately ARS 215,000 for Class I, ARS 276,800 for Class II, ARS 367,200 for Class III and ARS 513,000 for Class IV; approximately ARS 194,700 for IVD Groups A/B and ARS 241,200 for Groups C/D.

Three points require attention. First, fees are denominated in pesos and are frequently increased with inflation; a new schedule under Disposicion 5461/2026 has applied since 1 September 2026. Second, in addition to the registration fee, holders must pay an annual RPPTM registry maintenance fee, with reference amounts under Disposicion 5634/2024 of approximately ARS 39,500 for Class I and ARS 93,000 for Class IV, also subject to annual increases. Third, variations, renewals and certificate transfers each incur separate fees. Budgets should always be based on ANMAT’s current fee schedule.

Q20. How long is a registration valid, and how is it renewed?

A registration is valid for five years and may be renewed for an equal period. Renewal (revalidacion) must be requested within the prescribed window before expiry. GMC 25/21 refers only to the time limits in national health regulations, while the practical window is 90 days before expiry. Filing for renewal does not interrupt commercialisation, an important difference from markets such as Brazil.

If renewal is not completed before expiry, the registration lapses and the product must be registered again as new. Disposicion 2198/2022 expressly addresses this for IVDs. A company that stops selling the product should proactively request cancellation (cancelacion).

5. Imports and post-market obligations (Q21-Q24)

Registration is only the starting point. Import procedures and post-market vigilance are continuing compliance obligations.

Q21. How are products imported after registration?

The registration holder is the importer. Since mid-2025, import controls have been divided by risk class under Disposicion 4446/2025, effective in August 2025:

– Class I/II devices for commercial or free distribution no longer require prior ANMAT authorisation. Instead, the importer submits a sworn Aviso de Importacion (import notice) through the BONITA system within 48 hours after customs clearance. This reform covers approximately 70% of low-risk product import volume.

– Class III/IV devices, IVDs, temporary imports and unregistered samples still require prior ANMAT authorisation.

– Imports by direct users such as hospitals are submitted through the TAD system.

One strict rule applies to every shipment: the registration must be valid at the time of import. An expired registration directly blocks importation.

Q22. What post-market vigilance (tecnovigilancia) obligations apply?

Under Disposicion 8194/2023, published on 3 October 2023 and effective on 4 October 2023, and aligned with IMDRF N43 and ISO/TR 20416, the registration holder must:

Report through the ARGOS system within 48 hours any event that poses a serious threat to public health, and within 10 calendar days any event that causes the death or serious deterioration in health of a patient or user.

Notify ANMAT of a field safety corrective action (FSCA) within 10 calendar days of implementation and issue a field safety notice (FSN) to users without delay.

Maintain trend reporting. A statistically significant increase in the frequency or severity of non-serious events must also be reported.

Begin investigation and risk assessment without delay after reporting. Companies had 120 calendar days to adapt their quality management systems.

Violations may lead to preventive measures, sales prohibitions, suspension or cancellation of registrations, and penalties under Ley 16.463 and Decreto 341/92. ARGOS includes a public library, and FSCA reports are available to the public, making the compliance record publicly visible.

Q23. How should changes be managed?

Any modification must be notified to ANMAT within 30 business days of implementation. Where prior approval is required, the change may not be disclosed to the market until it has been officially published. Major changes, including relocation of a manufacturing site, significant design or material changes, and expanded indications, may require additional documents against the original registration requirements and, in extreme cases, a new registration.

At company authorisation level, a company using the simplified route under Disposicion 8799/2025 must replace its original sworn declaration with a new declaration within 30 days of any change in information, including its company name, legal address, additional premises, manufacturer or Technical Director.

Q24. Are there restrictions on advertising and promotion?

Yes, and they are often overlooked. Part IV of GMC 25/21 requires all medical device promotional information released to the market or consumers to be strictly consistent with the information submitted by the registration holder to the competent authority. Information requiring prior approval may not be disclosed until published through official channels. A mismatch between promotional claims and registration documents is a common compliance risk in Latin American markets.

6. Risks and registration holding strategy (Q25-Q26)

Avoiding common deficiency issues and selecting an appropriate holding structure are essential to project planning.

Q25. How should a local registration holder be selected, and can a certificate be transferred?

The structure must first be understood: in Argentina, the local importer and applicant holds the registration, and a foreign manufacturer cannot hold it directly. A registration transfer (transferencia) is procedurally available. ANMAT provides specific transfer procedures and fee items for Classes I, II, III and IV, for both domestic and imported products. However, the process requires cooperation from both parties, newly notarised authorisations, updated documents and fees, and generally takes approximately 1-2 months.

The principal risk is cooperation. If the existing holder is a distributor with tied commercial interests, a change in the commercial relationship can make a transfer difficult and may affect imports and sales during the process. A prudent structure separates regulatory registration holding from commercial distribution by using an independent, stable and professionally capable local entity for long-term holding, so that the registration does not automatically follow the distributor.

Q26. What are common reasons for deficiency notices or failed applications?

Industry experience identifies seven frequent issues:

1. Incomplete CFS or letter of authorisation authentication chains, including a missing apostille, missing translation or documents exceeding the two-year validity period.

2. Missing label elements, including importer information or the registration number, or non-standard Spanish.

3. An ISO 13485 certificate whose scope does not match the submitted products, or a certificate approaching expiry.

4. Poor-quality Spanish technical documentation, with terminology errors triggering deficiency requests.

5. Slow responses from the local registration holder, causing delayed corrections and repeated suspension of the review clock.

6. Incorrect classification, particularly for software, devices incorporating medicinal components and nanomaterial products.

7. Insufficient GMP evidence triggering a factory inspection with an unpredictable schedule.

7. Selecting a local compliance partner (Q27)

Because the local holder controls the registration, import rights and official ANMAT communications, provider selection should be treated as regulatory due diligence rather than solely a commercial decision.

Q27. What should manufacturers check when selecting an Argentina registration holder or compliance provider?

A neutral due diligence review should cover five areas:

• Local eligibility and independence: confirm that the Argentine entity holds the required operating authorisation and BPF/GMP certificate, can act as importer and registration holder, and has no distribution conflict that could obstruct a future transfer.
• Technical capability: verify experience with the 22 classification rules, Class III/IV technical review, IVD procedures, GMP evidence, CFS and letter of authorisation legalisation, and Spanish technical documentation and labelling.
• Submission and response capacity: confirm responsibility for HELENA or other applicable filings, deficiency responses, BONITA import notices and ARGOS vigilance reporting, with named personnel and defined response times.
• Lifecycle coverage: ensure that responsibilities include variations, annual registry maintenance, five-year renewals, cancellations and registration transfers.
• Contractual control: document registration ownership, access to dossiers and official correspondence, fees, cooperation duties, exit arrangements and transfer assistance.

This article is based on the ANMAT website, Argentina’s Official Gazette (including Disposiciones 64/2025, 8799/2025 and 4446/2025) and the original text of MERCOSUR GMC 25/21. Regulations were checked through October 2026. It is provided for general industry reference only and does not constitute legal or regulatory advice.